TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20822286

Group type: EXPERIMENTAL
Intervention: Self-esteem inconsistent feedback
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Social feedback (various operationalizations)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Acceptance signaling system
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Epistemic signaling system
Number of subjects: 0
Study: 17362423

Group type: EXPERIMENTAL
Intervention: Chewing paraffin wax for 10 minutes after stress loading
Number of subjects: 17

Group type: EXPERIMENTAL
Intervention: Light clenching for 3 minutes after stress loading
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control (no chewing)
Number of subjects: 17

Group type: COMPARATOR
Intervention: Control (rest periods during clenching)
Number of subjects: 17
Study: 15752881

Group type: COMPARATOR
Intervention: 68 Gy radiotherapy
Number of subjects: 669

Group type: EXPERIMENTAL
Intervention: 78 Gy radiotherapy
Number of subjects: 669

Group type: EXPERIMENTAL
Intervention: Both 68 Gy and 78 Gy radiotherapy
Number of subjects: 669
Study: 12046005

Group type: EXPERIMENTAL
Intervention: Quality circles (QCs) among first-year medical students, meeting once a week for 14 sessions of 45 minutes each.
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Quality circles (QCs) among first-year medical students.
Number of subjects: 135
Study: 10456621

Group type: EXPERIMENTAL
Intervention: Abrupt withdrawal of warfarin (group A)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Low fixed dose of warfarin (1.25 mg/day) for an additional month (group B)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Both groups (A and B)
Number of subjects: 41
Study: 7842190

Group type: EXPERIMENTAL
Intervention: Asthmaexpert (expert system)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Expert opinions
Number of subjects: 127
Study: 2404052

Group type: EXPERIMENTAL
Intervention: Low dose simvastatin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: High dose simvastatin
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Simvastatin (10 to 40 mg)
Number of subjects: 20
Study: 856370

Group type: EXPERIMENTAL
Intervention: Self-administered questionnaire on chest pain and intermittent claudication
Number of subjects: 18403

Group type: EXPERIMENTAL
Intervention: Self-administered questionnaire
Number of subjects: 18403
Study: 31007215

Group type: EXPERIMENTAL
Intervention: Topical Tacrolimus 0.03% ointment
Number of subjects: 90

Group type: COMPARATOR
Intervention: Topical Dexamethasone 0.05% ointment
Number of subjects: 90
Study: 28351204

Group type: EXPERIMENTAL
Intervention: Visi‐Pro Balloon‐Expandable Peripheral Stent System
Number of subjects: 75
Study: 25736724

Group type: EXPERIMENTAL
Intervention: NFCT
Number of subjects: 40
Study: 23559402

Group type: EXPERIMENTAL
Intervention: 5 mg oral dose of olanzapine
Number of subjects: 63
Study: 21616195

Group type: EXPERIMENTAL
Intervention: Structured meal‐plan‐based diet and supervised exercise program (SDE)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Meal‐replacement‐based diet program (MRP)
Number of subjects: 90
Study: 19220279

Group type: EXPERIMENTAL
Intervention: Cetilistat 50 mg t.i.d. (n = 7)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Cetilistat 60 mg t.i.d. (n = 9)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Cetilistat 100 mg t.i.d. (n = 7)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Cetilistat 120 mg t.i.d. (n = 9)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Cetilistat 150 mg t.i.d. (n = 16)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Cetilistat 240 mg t.i.d. (n = 9)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Cetilistat 300 mg t.i.d. (n = 9)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Orlistat 120 mg t.i.d. (n = 9)
Number of subjects: 99
Study: 17427819

Group type: EXPERIMENTAL
Intervention: F2000 (3M ESPE)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Dyract AP (Dentsply)
Number of subjects: 33
Study: 15209321

Group type: EXPERIMENTAL
Intervention: Verbal content cues training
Number of subjects: 0

Group type: COMPARATOR
Intervention: No cue training (Control)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Visual and vocal content cues training
Number of subjects: 0
Study: 11561263

Group type: EXPERIMENTAL
Intervention: 40 mL bupivacaine 0.25% plus fentanyl 2.5 microg/mL (group BF)
Number of subjects: 60

Group type: COMPARATOR
Intervention: 40 mL bupivacaine 0.25% (group B)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: 40 mL bupivacaine 0.125% plus fentanyl 2.5 microg/mL (group DBF)
Number of subjects: 60
Study: 9628078

Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral psychotherapy (CBT)
Number of subjects: 17
Study: 7930046

Group type: EXPERIMENTAL
Intervention: Initial expression condition
Number of subjects: 0

Group type: COMPARATOR
Intervention: Initial suppression condition
Number of subjects: 0
Study: 3421199

Group type: EXPERIMENTAL
Intervention: 6% carbohydrate-electrolyte beverage (MC)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Water placebo (P)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2.5% carbohydrate-electrolyte beverage (LC)
Number of subjects: 0
Study: 29703289

Group type: EXPERIMENTAL
Intervention: Group 1 (ocular bandage gel 4 times a day for 14 days and bandage contact lens)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Group 2 (ocular bandage gel 4 times a day for 14 days)
Number of subjects: 39

Group type: COMPARATOR
Intervention: Group 3 (control; bandage contact lens and artificial tears 4 times a day for 14 days)
Number of subjects: 39
Study: 27993177

Group type: EXPERIMENTAL
Intervention: High-resistant starch diet with lower carbohydrate intake
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: High-resistant starch diet with higher carbohydrate intake
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: High-resistant starch meal with lower carbohydrate intake
Number of subjects: 52

Group type: COMPARATOR
Intervention: High-resistant starch diet
Number of subjects: 52
Study: 24622164

Group type: EXPERIMENTAL
Intervention: Crisis resource management instruction (1 hour)
Number of subjects: 15

Group type: COMPARATOR
Intervention: No additional training (Control)
Number of subjects: 15
Study: 23516685

Group type: EXPERIMENTAL
Intervention: Biofeedback
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Hypnotherapy
Number of subjects: 97

Group type: COMPARATOR
Intervention: Comparison between Biofeedback and Hypnotherapy
Number of subjects: 97

Group type: EXPERIMENTAL
Intervention: Biofeedback and Hypnotherapy
Number of subjects: 97
Study: 19877267

Group type: EXPERIMENTAL
Intervention: 4.0 mm everolimus-eluting stent (EES)
Number of subjects: 69

Group type: COMPARATOR
Intervention: TAXUS EXPRESS(2) paclitaxel-eluting stent (PES)
Number of subjects: 69

Group type: EXPERIMENTAL
Intervention: 4.0 mm EES
Number of subjects: 69

Group type: COMPARATOR
Intervention: PES
Number of subjects: 69
Study: 18798783

Group type: EXPERIMENTAL
Intervention: Everest system
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Lava system
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Procera system
Number of subjects: 45

Group type: COMPARATOR
Intervention: Comparison of CAD/CAM systems
Number of subjects: 45

Group type: COMPARATOR
Intervention: Time phases
Number of subjects: 45
Study: 16076697

Group type: EXPERIMENTAL
Intervention: Sequential, dose-dense epirubicin plus docetaxel
Number of subjects: 34
Study: 11920355

Group type: EXPERIMENTAL
Intervention: 7.5% icodextrin solution (Extraneal)
Number of subjects: 39

Group type: COMPARATOR
Intervention: 2.27% glucose solution
Number of subjects: 39
Study: 10336842

Group type: EXPERIMENTAL
Intervention: C1165G polymorphism in the beta1-adrenoceptor gene
Number of subjects: 426

Group type: COMPARATOR
Intervention: Control subjects (age- and sex-matched)
Number of subjects: 426
Study: 8529496

Group type: EXPERIMENTAL
Intervention: Chromium supplementation (220 micrograms elemental chromium daily for 90 days)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 1760827

Group type: EXPERIMENTAL
Intervention: verapamil 120 sustained-release
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: combination therapy (ISDN + verapamil)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: ISDN retard 120
Number of subjects: 30
Study: 7161777

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) 7.5 to 25 mg oral or intramuscular
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 21
Study: 31445787

Group type: EXPERIMENTAL
Intervention: Total elbow arthroplasty (TEA)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Open reduction-internal fixation (ORIF)
Number of subjects: 42
Study: 29565948

Group type: EXPERIMENTAL
Intervention: 40 mg SR-nitrite, BID
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: 80 mg SR-nitrite, BID
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 25378638

Group type: COMPARATOR
Intervention: Control (Solitaire stentriever plus guide catheter)
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Control plus proximal Funnel placement
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Control plus distal Funnel placement
Number of subjects: 45
Study: 23347253

Group type: EXPERIMENTAL
Intervention: 1410 nm fractional photothermolysis laser at 20 mJ, 5% coverage
Number of subjects: 30

Group type: COMPARATOR
Intervention: 1410 nm fractional photothermolysis laser at 20 mJ, 20% coverage
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 1410 nm fractional photothermolysis laser (both sides)
Number of subjects: 30
Study: 23161296

Group type: EXPERIMENTAL
Intervention: Information video (n=124)
Number of subjects: 227

Group type: COMPARATOR
Intervention: Verbal information (n=103)
Number of subjects: 227
Study: 20709946

Group type: EXPERIMENTAL
Intervention: Psychoeducational interventions
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Skills training interventions
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Therapeutic counseling interventions
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Various interventions (jointly delivered to patients and caregivers)
Number of subjects: 29
Study: 17492467

Group type: EXPERIMENTAL
Intervention: ATTG(2)/ATTGT(2) and GG genotypes of NF-kappaB1 and NF-kappaBIalpha
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: NF-kappaB1 ATTG(2)/ATTG(2) and NF-kappaBIalpha GG genotypes
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: ATTG(1)/ATTG(1) genotype
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: NF-kappaBIalpha GG genotype
Number of subjects: 185

Group type: EXPERIMENTAL
Intervention: NF-kappaBIalpha genotypes
Number of subjects: 185
Study: 16834832

Group type: EXPERIMENTAL
Intervention: Escitalopram (20 mg)
Number of subjects: 459

Group type: COMPARATOR
Intervention: Paroxetine (40 mg)
Number of subjects: 459
Study: 12595814

Group type: EXPERIMENTAL
Intervention: Selective phosphodiesterase type-5 inhibitors
Number of subjects: 0
Study: 10893703

Group type: EXPERIMENTAL
Intervention: Racemic ketamine 0.3 mg/kg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Pethidine 0.7 mg/kg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: (R)-ketamine 0.5 mg/kg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: (S)-ketamine 0.15 mg/kg
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: (R)-ketamine
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: (S)-ketamine
Number of subjects: 20
Study: 8929195

Group type: EXPERIMENTAL
Intervention: Upright posture at altitude (ALT)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Supine posture at altitude (ALT)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Supine posture at sea level (SL)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Upright posture at sea level (SL)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: All groups combined at altitude (ALT)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: All groups combined at sea level (SL)
Number of subjects: 18
Study: 1486186

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg once daily in the morning
Number of subjects: 226

Group type: COMPARATOR
Intervention: Ranitidine 300 mg once daily at night
Number of subjects: 226
Study: 6489418

Group type: EXPERIMENTAL
Intervention: 22 registered pharmaceutical specialities
Number of subjects: 50

Group type: COMPARATOR
Intervention: Generic equivalents
Number of subjects: 50
Study: 30625145

Group type: EXPERIMENTAL
Intervention: Cumulative adversity score (each additional adversity)
Number of subjects: 1726
Study: 29193527

Group type: EXPERIMENTAL
Intervention: Telemedicine intervention for diabetes foot ulcer care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telemedicine intervention in home-based care
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Telemedicine intervention
Number of subjects: 0
Study: 27459498

Group type: EXPERIMENTAL
Intervention: Dry graft tympanoplasty
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Wet graft tympanoplasty
Number of subjects: 100
Study: 25201587

Group type: EXPERIMENTAL
Intervention: Radioguided seed localization (RSL)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Wire localization (WL)
Number of subjects: 73
Study: 21900224

Group type: EXPERIMENTAL
Intervention: Internal Limiting Membrane (ILM) peeling
Number of subjects: 141

Group type: COMPARATOR
Intervention: No peeling
Number of subjects: 141
Study: 20536946

Group type: EXPERIMENTAL
Intervention: Improvement of IGT
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Baseline characteristics of children who improved IGT
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Follow-up characteristics of children who improved IGT
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Pubertal stage
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Predictive factors for normalization of IGT
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Cardiovascular risk factors and HOMA
Number of subjects: 79
Study: 17663104

Group type: EXPERIMENTAL
Intervention: Routine obstetric treatment with catgut embedding at Zusanli (ST 36) and Shangjuxu (ST 37)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Routine obstetric treatment
Number of subjects: 300
Study: 16091264

Group type: EXPERIMENTAL
Intervention: Priming of the position (subliminal and supraliminal)
Number of subjects: 0

Group type: COMPARATOR
Intervention: No priming of the position
Number of subjects: 0
Study: 12017421

Group type: EXPERIMENTAL
Intervention: Pramlintide 75-microg
Number of subjects: 538

Group type: EXPERIMENTAL
Intervention: Pramlintide 150-microg
Number of subjects: 538

Group type: EXPERIMENTAL
Intervention: Pramlintide (all doses)
Number of subjects: 538

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 538
Study: 9890379

Group type: EXPERIMENTAL
Intervention: IV Ondansetron (4 mg)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 7675936

Group type: EXPERIMENTAL
Intervention: 3 IU AVP
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: 150 micrograms ANH
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study: 1646490

Group type: EXPERIMENTAL
Intervention: Subcutaneous low molecular weight heparin (CY 216)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Continuous intravenous unfractionated heparin
Number of subjects: 166
Study: 6752926

Group type: EXPERIMENTAL
Intervention: Antrafenine (up to 1200 mg daily)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Paracetamol (up to 4 g daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 31365565

Group type: EXPERIMENTAL
Intervention: 150 hours of mentored clinical practice
Number of subjects: 441

Group type: COMPARATOR
Intervention: Usual training (control)
Number of subjects: 441

Group type: EXPERIMENTAL
Intervention: Intervention (150 hours of mentored clinical practice)
Number of subjects: 441
Study: 29130845

Group type: EXPERIMENTAL
Intervention: Restrictive red-cell transfusion strategy (transfuse if hemoglobin <7.5 g/dL)
Number of subjects: 5243

Group type: COMPARATOR
Intervention: Liberal red-cell transfusion strategy (transfuse if hemoglobin <9.5 g/dL in operating room or ICU, <8.5 g/dL in non-ICU ward)
Number of subjects: 5243

Group type: EXPERIMENTAL
Intervention: Restrictive red-cell transfusion strategy
Number of subjects: 5243

Group type: COMPARATOR
Intervention: Liberal red-cell transfusion strategy
Number of subjects: 5243
Study: 26559533

Group type: EXPERIMENTAL
Intervention: Ginkgo biloba extract (EGb761) with methylprednisolone
Number of subjects: 56

Group type: COMPARATOR
Intervention: Placebo with methylprednisolone
Number of subjects: 56
Study: 23975474

Group type: EXPERIMENTAL
Intervention: Pharmaceutical care (PC) using the Dáder method
Number of subjects: 94

Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Subgroup of patients with therapeutic failure and non-adherence at the beginning of the trial (N = 50)
Number of subjects: 94
Study: 23027071

Group type: EXPERIMENTAL
Intervention: Hybrid minimally invasive oesophagectomy (HMIO)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Open surgery (control)
Number of subjects: 0
Study: 19535242

Group type: EXPERIMENTAL
Intervention: Tamoxifen (2 years)
Number of subjects: 564

Group type: COMPARATOR
Intervention: Control
Number of subjects: 564
Study: 17513805

Group type: EXPERIMENTAL
Intervention: Six cycles of epirubicin 75 mg/m2 and docetaxel 75 mg/m2 on day 1 and granulocyte colony‐stimulating factor on days 3 through 10 (ED+G), every 21 days
Number of subjects: 288

Group type: COMPARATOR
Intervention: Three cycles of epirubicin 75 mg/m2 and docetaxel 75 mg/m2 on day 1 and granulocyte colony‐stimulating factor on days 3 through 10 (ED+G), every 21 days
Number of subjects: 288

Group type: EXPERIMENTAL
Intervention: Six cycles of ED+G
Number of subjects: 288

Group type: COMPARATOR
Intervention: Three cycles of ED+G
Number of subjects: 288
Study: 15208047

Group type: EXPERIMENTAL
Intervention: Lower-dose formulation of Depo-Provera (104 mg/0.65 mL)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Original formulation of Depo-Provera (150 mg/mL)
Number of subjects: 0
Study: 11782825

Group type: EXPERIMENTAL
Intervention: Above-motor-threshold TENS
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Below-motor-threshold TENS
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Perception-threshold TENS
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 40
Study: 9830248

Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 135

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 135

Group type: COMPARATOR
Intervention: No alcohol
Number of subjects: 135
Study: 11271342

Group type: EXPERIMENTAL
Intervention: FK 506
Number of subjects: 81

Group type: COMPARATOR
Intervention: CyA/AzA
Number of subjects: 81
Study: 2567049

Group type: EXPERIMENTAL
Intervention: sulphasalazine
Number of subjects: 54

Group type: COMPARATOR
Intervention: D-penicillamine
Number of subjects: 54
Study: 30894004

Group type: EXPERIMENTAL
Intervention: Enhanced Primary Care + Coaching (EPC + C)
Number of subjects: 360

Group type: COMPARATOR
Intervention: Enhanced Primary Care (EPC)
Number of subjects: 360
Study: 28640168

Group type: EXPERIMENTAL
Intervention: BIS monitoring in MST
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: BIS monitoring in ECT
Number of subjects: 20

Group type: COMPARATOR
Intervention: no-BIS monitoring in MST
Number of subjects: 20

Group type: COMPARATOR
Intervention: no-BIS monitoring in ECT
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: BIS condition
Number of subjects: 20

Group type: COMPARATOR
Intervention: no-BIS condition
Number of subjects: 20
Study: 26538423

Group type: EXPERIMENTAL
Intervention: High-dose hemithoracic radiotherapy
Number of subjects: 151

Group type: COMPARATOR
Intervention: No radiotherapy
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy and extrapleural pneumonectomy
Number of subjects: 151

Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy
Number of subjects: 151
Study: 23744726

Group type: EXPERIMENTAL
Intervention: Exenatide plus metformin
Number of subjects: 174

Group type: COMPARATOR
Intervention: Placebo plus metformin
Number of subjects: 174
Study: 21295742

Group type: EXPERIMENTAL
Intervention: Soy isoflavones 120 mg/d
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Soy isoflavones 80 mg/d
Number of subjects: 171

Group type: EXPERIMENTAL
Intervention: Soy isoflavones (both doses)
Number of subjects: 171

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study: 19426751

Group type: EXPERIMENTAL
Intervention: Composite face stimuli with horizontal and vertical misalignment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Composite face stimuli with stereo-depth separation
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Composite face stimuli slanted through stereo-depth
Number of subjects: 0
Study: 16991073

Group type: EXPERIMENTAL
Intervention: PFN
Number of subjects: 240

Group type: COMPARATOR
Intervention: GLN
Number of subjects: 240
Study: 15493037

Group type: EXPERIMENTAL
Intervention: 30 Gy per 10 fractions (n = 110)
Number of subjects: 214

Group type: COMPARATOR
Intervention: 40 Gy per 20 fractions (n = 104)
Number of subjects: 214
Study: 15278681

Group type: EXPERIMENTAL
Intervention: Serum cytokine measurements (IL-1beta, TNFalpha, IL-6)
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Baseline serum IL-6
Number of subjects: 118

Group type: EXPERIMENTAL
Intervention: Serum cytokine concentrations
Number of subjects: 118
Study: 10030393

Group type: EXPERIMENTAL
Intervention: E3/E3 genotype
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: E3/E4 genotype
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: E2/3 genotype
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: APOE E4 allele presence
Number of subjects: 142

Group type: EXPERIMENTAL
Intervention: Environmental factors (diet and lifestyle)
Number of subjects: 142
Study: 7588455

Group type: EXPERIMENTAL
Intervention: Vigabatrin (VGB)
Number of subjects: 111

Group type: COMPARATOR
Intervention: Concomitant b.i.d. medications
Number of subjects: 111

Group type: COMPARATOR
Intervention: Thrice-daily (t.i.d.) medications
Number of subjects: 111

Group type: COMPARATOR
Intervention: Four times daily (q.i.d.) medications
Number of subjects: 111
Study: 2351342

Group type: EXPERIMENTAL
Intervention: Protocol A (modified Program 1 plus isoradial chamber)
Number of subjects: 20
Study: 458990

Group type: EXPERIMENTAL
Intervention: Emepronium bromide
Number of subjects: 15

Group type: COMPARATOR
Intervention: Flavoxate hydrochloride
Number of subjects: 15

Group type: COMPARATOR
Intervention: Imipramine hydrochloride
Number of subjects: 15